Retracted
Main Authors: | Samah Elsaadi, Kristine Misund, Pegah Abdollahi, Esten Nymoen Vandsemb, Siv Helen Moen, Anna Kusnierczyk, Geir Slupphaug, Therese Standal, Anders Waage, Tobias S Slørdahl, Even Rustad, Anders Sundan, Carl Hay, Alwin G Schuller, Alexandra Borodovsky, Eline Menu, Magne Børset, Anne Marit Sponaas |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/1/e0637-6ret.full |
Similar Items
-
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
by: Samah Elsaadi, et al.
Published: (2020-06-01) -
Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
by: Anne Marit Sponaas, et al.
Published: (2021-02-01) -
Targeting phosphoglycerate dehydrogenase in multiple myeloma
by: Samah Elsaadi, et al.
Published: (2021-01-01) -
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy.
by: Anne-Marit Sponaas, et al.
Published: (2015-01-01) -
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
by: Thea Kristin Våtsveen, et al.
Published: (2016-08-01)